GlassScriptPhysician profile
Amal Sarah
NPI 1568469849
$2,072.40
in general payments reported to CMS, 2019-2025
26 companies · $99.30 in 2025
The $99.30 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $238 · 2021: $352 · 2022: $491 · 2023: $378 · 2024: $299 · 2025: $99.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $776.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $572.44 | 2021-2023 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $346.73 | 2019-2024 | Breztri, Airsupra |
| Abbott Laboratories | $257.56 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $213.68 | 2019-2023 | Wegovy |
| Pfizer INC. | $139.38 | 2019-2023 | |
| Genzyme Corporation | $79.63 | 2020 | |
| Amgen INC. | $54.41 | 2019-2021 | |
| Exact Sciences Corporation | $50.19 | 2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $35.59 | 2019-2022 | |
| Axsome Therapeutics, INC. | $32.19 | 2023 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.85 | 2019-2023 | Xifaxan |
| Ethicon INC. | $30.41 | 2023 | Monarch Platform |
| Astellas Pharma US INC | $27.28 | 2019 | |
| Janssen Pharmaceuticals, INC | $26.45 | 2019 | |
| Inari Medical, INC. | $20.33 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $18.78 | 2020 | |
| Sanofi-Aventis U.S. LLC | $18.75 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.01 | 2023 | Gvoke Hypopen |
| Heartflow, INC. | $16.21 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $14.30 | 2020 | |
| Lilly USA, LLC | $13.93 | 2023 | Mounjaro |
| Amarin Pharma, INC. | $12.60 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.73 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.54 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.19 | 2021 | |
| Dynavax Technologies Corporation | $7.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amal Sarah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.